APA citiranje

Abdelaziz, L. A., Taha, H. F., Ali, M. M., Abdelgawad, M. I., & Elwan, A. (2021). Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: A prospective randomized multi-centric Egyptian study. Contemp Oncol (Pozn).

Citação norma Chicago

Abdelaziz, Lobna A., Heba F. Taha, Magid M. Ali, Marwa I. Abdelgawad, and Amira Elwan. "Tolerability and Outcome of Sunitinib By Giving 4/2 Schedule Versus 2/1 Schedule in Metastatic Renal Cell Carcinoma Patients: A Prospective Randomized Multi-centric Egyptian Study." Contemp Oncol (Pozn) 2021.

MLA citiranje

Abdelaziz, Lobna A., et al. "Tolerability and Outcome of Sunitinib By Giving 4/2 Schedule Versus 2/1 Schedule in Metastatic Renal Cell Carcinoma Patients: A Prospective Randomized Multi-centric Egyptian Study." Contemp Oncol (Pozn) 2021.